Biohaven share price today
(NASDAQ: BHVN)

Name: Biohaven Share Price Today (NASDAQ: BHVN) - Biohaven Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Biohaven share price is $40.71 & ₹3,521.01 as on 24 Jan 2025, 2.30 'hrs' IST

$40.71

▲

0.15

(0.37%)

Market is closed - opens 8 PM, 24 Jan 2025

View live Biohaven share price in Dollar and Rupees. Guide to invest in Biohaven stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Biohaven, along with analyst recommendations, forecasts, and comprehensive financials.

Biohaven share price movements

Today's Low: $39.06
Today's High: $41.35
$40.71
4.07%
Downside
Day's Volatility :5.55%
Upside
1.55%
52 Weeks Low: $26.80
52 Weeks High: $62.21
$40.71
34.17%
Downside
52 Weeks Volatility :56.92%
Upside
34.56%

Biohaven Returns

Period	Biohaven Ltd	Index (Russel 2000)
3 Months	-23.24%	0.0%
6 Months	-1.58%	0.0%
1 Year	-9.81%	0.0%
3 Years	-65.14%	-11.0%

Biohaven Key Statistics

in dollars & INR

Previous Close	$40.56
Open	$40.04
Today's High	$41.35
Today's Low	$39.055
Market Capitalization	$3.9B
Today's Volume	$1.0M
52 Week High	$62.21
52 Week Low	$26.8
Revenue TTM	$0.0
EBITDA	$-841.6M
Earnings Per Share (EPS)	$-9.37
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-265.45%

How to invest in Biohaven Stock (BHVN) from India?

It is very easy for Indian residents to invest directly in Biohaven from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Biohaven stock in both Indian Rupees (INR) and US Dollars (USD). Search for Biohaven or BHVN on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Biohaven or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Biohaven shares which would translate to 0.021 fractional shares of Biohaven as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Biohaven, in just a few clicks!

Returns in Biohaven for Indian investors in Rupees

Investment Value

₹1,00,000

Biohaven investment value today

Current value as on today

₹94,581

Returns

₹5,419

(-5.42%)

Returns from Biohaven Stock

₹9,473 (-9.47%)

Dollar Returns

₹4,054 (+4.05%)

Indian investors sentiment towards Biohaven

102%

Period: Oct 25, 2024 to Jan 23, 2025. Change in 30 Days versus previous period

Search volume for Biohaven on INDmoney from India has grown in the last 30 days as on Jan 24, 2025. 102% more investors are searching Biohaven in the last 30 days versus the previous period.

Global Institutional Holdings in Biohaven

Vanguard Group Inc
7.70%
BlackRock Inc
6.80%
Stifel Financial Corp
6.44%
HHG PLC
6.16%
Suvretta Capital Management, LLC
5.14%
Farallon Capital Management, L.L.C.
3.60%

Analyst Recommendation on Biohaven

Buy

94%Buy

5%Hold

0%Sell

Based on 17 Wall street analysts offering stock ratings for Biohaven(by analysts ranked 0 to 5 stars)

Based on 17 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Biohaven

What analysts predicted

Upside of 60.37%

Target:

$65.29

Current:

$40.71

Insights on Biohaven

Price Movement
In the last 7 days, BHVN stock has moved up by 13.1%
BHVN vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 40.5% return, outperforming this stock by 56.5%
BHVN vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 95.4% return, outperforming this stock by 158.6%

Biohaven Technicals Summary

Sell

Neutral

Buy

Biohaven is currently in a neutral trading position according to technical analysis indicators.

Biohaven Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Biohaven Ltd	11.37%	-1.58%	-9.81%	-65.14%	-23.83%
Biontech Se	0.91%	34.01%	18.85%	-26.4%	246.9%
Regeneron Pharmaceuticals, Inc.	-4.82%	-36.95%	-28.33%	12.74%	100.35%
Vertex Pharmaceuticals Incorporated	4.86%	-13.58%	-0.46%	88.45%	88.24%
Alnylam Pharmaceuticals, Inc.	9.57%	13.5%	44.91%	103.56%	127.75%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Biohaven Ltd	NA	NA	NA	-8.49	-2.65	-1.19	NA	3.33
Biontech Se	160.8	NA	0.04	-3.33	-0.02	-0.01	NA	79.73
Regeneron Pharmaceuticals, Inc.	17.02	17.02	1.05	44.99	0.17	0.07	NA	272.04
Vertex Pharmaceuticals Incorporated	32.84	NA	1.1	0.48	-0.03	0.12	NA	60.65
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.18	-15.01	-0.03	NA	0.25

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Biohaven Ltd	Buy	$3.9B	-23.83%	NA	0.0%
Biontech Se	Buy	$28.1B	246.9%	160.8	-15.36%
Regeneron Pharmaceuticals, Inc.	Buy	$75.6B	100.35%	17.02	33.61%
Vertex Pharmaceuticals Incorporated	Buy	$110.2B	88.24%	32.84	-4.51%
Alnylam Pharmaceuticals, Inc.	Buy	$34.2B	127.75%	NA	-15.86%

Biohaven Dividend announcements

Biohaven Earnings
Biohaven’s price-to-earnings ratio stands at None
Read More

About Biohaven

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut. Biohaven Ltd. was formerly a subsidiary of Biohaven Pharmaceutical Holding Company Ltd.

Organization	Biohaven
Employees	239
CEO	Dr. Vladimir Coric M.D.
Industry	Health Technology

Management People of Biohaven

Name	Title
Dr. Vladimir Coric M.D.	Chairman & CEO
Mr. Matthew Buten	Chief Financial Officer
Dr. Bruce D. Car DACVP, Ph.D.	Chief Scientific Officer
Ms. Kimberly Gentile	Senior Vice President of Clinical Operations
Ms. Deb Young	Director of Regulatory Affairs & Operations
Mr. George C. Clark	VP & Chief Accounting Officer
Ms. Jennifer Porcelli	Vice President of Investor Relations
Mr. Warren Volles J.D.	General Counsel & Chief Legal Officer
Mr. Clifford Bechtold M.S.	President, GM of Biohaven Ireland & Chief Compliance Officer
Mr. John Tilton	Chief Commercial Officer of Rare Diseases

Important FAQs about investing in Biohaven (BHVN) from India :

What is Biohaven share price today?

Biohaven share price today stands at $40.71, Open: $40.04 ; Previous Close: $40.56 ; High: $41.35 ; Low: $39.06 ; 52 Week High: $62.21 ; 52 Week Low: $26.80. The stock opens at $40.04, after a previous close of $40.56. The stock reached a daily high of $41.35 and a low of $39.06, with a 52-week high of $62.21 and a 52-week low of $26.80.

Can Indians buy Biohaven shares?

Yes, Indians can invest in the Biohaven (BHVN) from India.

With INDmoney, you can buy Biohaven at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Biohaven at zero transaction cost.

How can I buy Biohaven shares from India?

It is very easy to buy Biohaven from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Biohaven be purchased?

Yes, you can buy fractional shares of Biohaven with INDmoney app.

What are the documents required to start investing in Biohaven stocks?

To start investing in Biohaven, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.